Agios Pharmaceuticals Inc (AGIO) : Simplex Trading scooped up 15,604 additional shares in Agios Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 27,905 shares of Agios Pharmaceuticals Inc which is valued at $1,470,314.Agios Pharmaceuticals Inc makes up approximately 0.19% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , First Mercantile Trust Co added AGIO to its portfolio by purchasing 2,600 company shares during the most recent quarter which is valued at $136,994. Agios Pharmaceuticals Inc makes up approx 0.02% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in AGIO in the latest quarter, The investment management firm added 2,440 additional shares and now holds a total of 14,388 shares of Agios Pharmaceuticals Inc which is valued at $782,707.
Agios Pharmaceuticals Inc closed down -1.11 points or -2.06% at $52.69 with 6,19,050 shares getting traded on Friday. Post opening the session at $53.91, the shares hit an intraday low of $51.26 and an intraday high of $54.015 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Agios Pharmaceuticals Inc reported $-1.47 EPS for the quarter, missing the analyst consensus estimate by $ -0.17 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.30. The company had revenue of $6.97 million for the quarter, compared to analysts expectations of $41.37 million. The company’s revenue was down -47.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.85 EPS.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.